Joule Unlimited, Inc.

Joule on Pace to Produce Solar Fuels at Productivities Far Exceeding Those of All Known Biofuel Processes

Joule on Pace to Produce Solar Fuels at Productivities Far Exceeding Those of All Known Biofuel Processes

February 17, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today supported the high-productivity potential of its production process with the publication of a detailed analysis and model of its breakthrough solar-to-fuels platform.

BG Medicine, Inc.

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

February 16, 2011

WALTHAM, Mass., Feb. 16, 2011 (GLOBE NEWSWIRE) -- BG Medicine (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers, today announced the issuance of U.S. Patent No. 7,888,137, entitled "Method For Identifying a Subject at Risk of Developing Heart Failure by Determining the Level of Galectin-3 or Thrombospondin-2" to the University of Maastricht. BG Medicine has an exclusive license to this issued patent, which pertains to galectin-3 testing for individuals at risk for heart failure.

AVEO Pharmaceuticals, Inc.

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

February 16, 2011

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, “Astellas”), a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO, “AVEO”) today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

BG Medicine, Inc.

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

February 9, 2011

WALTHAM, Mass.--(BUSINESS WIRE)-- BG Medicine (NASDAQ: BGMD) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.

Novomer, Inc.

Novomer Wins InformexUSA Sustainability Award

Novomer Wins InformexUSA Sustainability Award

February 9, 2011

BOSTON, MA--(Marketwire - February 9, 2011) - Novomer Inc., a sustainable materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), today announced that it has been recognized with a InformexUSA 2011 Profiles in Sustainability Award. Novomer was honored during the show's awards gala held last night at the Charlotte Convention Center.

Affinnova, Inc.

Affinnova Triples the Likelihood of Beating Leading Competitors

Affinnova Triples the Likelihood of Beating Leading Competitors

February 9, 2011

Waltham, MA, February 09, 2011 – Affinnova, the global leader in marketing innovation software and services, today announced that 64% of client initiatives using their IDDEA software produce optimized concepts that outscore their leading competitor. Conversely, pre-optimization concepts from the same initiatives beat their leading competitor only 22% of the time. These findings are the result of a yearlong study of all client initiatives using Affinnova’s IDDEA II software with competitive benchmark measurement capabilities.

LS9

LS9 Announces Second Partnership with Procter & Gamble

LS9 Announces Second Partnership with Procter & Gamble

February 7, 2011

SOUTH SAN FRANCISCO, CA - February 7, 2011 - LS9, Inc. today announced the initiation of a second development and commercialization partnership with Procter & Gamble (NYSE: PG). This additional partnership draws on LS9's unique technology to broaden the portfolio of renewable chemicals to be used in P&G's consumer products.

Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

February 7, 2011

 

BG Medicine, Inc.

BG Medicine Announces Pricing of Initial Public Offering

BG Medicine Announces Pricing of Initial Public Offering

February 4, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

February 1, 2011

CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).